Umbilical cord blood (UCB) is a source of hematopoietic stem cells (HSCs) used for allogeneic transplantation of patients with hematological diseases. Public cord blood banks (CBB) have been established worldwide to collect, cryopreserve and store UCB units for future transplantation.
UCB unit selection by a transplant center is primarily based on donor-recipient HLA compatibility and pre-freezing total nucleated cells (TNC) content. However, UCB units can be stored for long periods before their use for transplantation and potentially be exposed to temperatures outside the recommended range, resulting in an alteration of graft quality. 1 CBBs must therefore establish a quality control to assess the quality of the UCB units before their release for transplantation. The use of an attached segment (AS) to the UCB unit, containing an aliquot of the cryopreserved product, is proposed as a quality control. 2 This quality control consists of determining cell viability and/or clonogenic potential to confirm the effectiveness of the UCB unit selected for clinical use. 3 However, this control is still controversial with results difficult to compare because of the diversity of quality control techniques used. [3] [4] [5] [6] [7] [8] [9] The UCB manipulation methods probably impact on results that would require consideration of harmonizing practices. 10 The objective of this study was to determine if the TNC and CD34+ cell viabilities obtained from the AS are representative of the viabilities obtained from the main bag. For this, we retrospectively analyzed UCB units of our CBB released and thawed for transplantation as well as UCB units that were disqualified for therapeutic use.
UCBs were collected by trained staff in eight authorized maternity clinics affiliated with Saint-Louis Hospital CBB (Paris, France) after mothers' written informed consent was obtained in accordance with French Health Authorities policies. The UCB units were plasma and RBCs reduced, frozen within 24 h after collection and stored in nitrogen vapor. There are two AS: proximal and distal, depending on the distance from the main bag. The determination of CD34+/CD45+ cell numbers was performed in accordance with ISHAGE (International Society for Hematology and Graft Engineering) guidelines for gating. Viability testing was performed with the fluorescent dye 7-AAD. The CBB was licensed by the French regulatory agency. The UCB units were assessed against the French Code for Good Manufacturing Practice.
Firstly, to determine whether AS was representative of the bags, we compared TNC and CD34+ cell viabilities obtained by the transplant center after UCB thawing to viabilities obtained by our CBB on the AS before release. TNC viability obtained from bag was significantly higher than that obtained from AS, 64.3 ± 20.5% vs 49.8 ± 12.3%, respectively (Po0.0001; Figure 1a) . Similarly, CD34+ cell viability was significantly higher in the bag compared to that of the AS, 88.6 ± 6.2% vs 70.4 ± 14.2% (P = 0.0005; Figure 1a ). This difference was observed whatever the quality control technique used (7-AAD, trypan blue, propidium iodide) (data not shown). Concerning clinical aspects, transplantation results with these UCB are consistent with the published data (data from Center for International Blood and Marrow Transplant Research or 11 ): median time to recovery was 24 days (7-58) for neutrophils and 40 days (2-135) for platelets. Bag TNC viability, as well as that of the AS, did not correlate with time to neutrophil recovery (P = 0.1682 and P = 0.5415, respectively) or with time to platelet recovery (P = 0.6699 and P = 0.1450, respectively).
However, comparison of the viabilities between bag and AS in the context of grafted UCB is questionable, since the viability determination is performed by different laboratories using different methods of analysis. Thus, in a second step, we analyzed the results of UCB, which was processed and thawed in our laboratory in the context of our quality control program. As shown in Figure 1b , TNC and CD34+ cell viability obtained from the bag was significantly higher than that obtained from distal and proximal AS (for TNC, bag: 62.4 ± 11.9%; distal AS: 53.2 ± 16.0% and proximal AS: 52.4 ± 15.6%, P o0.0001 and P o0.0001, respectively; for CD34+ cells, bag: 88.2 ± 10.2%; distal AS: 54.8 ± 25.6% and proximal AS: 65.7 ± 27.4%, Po 0.0001 and Po 0.0001, respectively).
Finally, since 2008, the recruitment for transplant of nine qualified UCB units was canceled by the transplant center due to low viability after the thawing of AS. Since these UCB units cannot be used for transplantation, we thawed them to assess the quality of the bag. The comparison of cell viability results between bag and distal/proximal AS showed a significant difference (Figure 1c ). Cell viabilities of bag were significantly higher than those of distal or proximal AS, both for the TNC (bag: 61.4 ± 11.6%; distal AS: 36.8 ± 9.6% and proximal AS: 36.7 ± 14.5%; P = 0.0008 and P = 0.0053 respectively) and CD34+ cells (bag: 87.3 ± 12.6%; distal AS: 28.5 ± 9.0% and proximal AS: 38.6 ± 26.5%; Po0.0001 and P = 0.0006, respectively). TNC and CD34+ cell viability obtained from bag of these UCB units were found to be in accordance with our specifications. Moreover, TNC and CD34+ cell recoveries (70.1 ± 18.8% and 140.8 ± 33.6%, respectively) demonstrate that the quantity of injected cells should have been sufficient to ensure engraftment.
With HSC transplant improvement, the UCB selection knowledge has evolved. Since the recommendations made in 2004, criteria have become more drastic regarding HLA matching between donor and recipient, cellular dose, or qualified controls performed prior to UCB recruitment. 2, 12 In 2010, Scaradavou et al. 13 showed the importance of obtaining a CD34+ cell viability 475% as a criterion for success of the HSC transplant. Thus, it appeared important to determine the quality of the UCBs prior to their recruitment. One of the means is to quantify the viability of cells contained in AS.
14 Currently, the tests carried out systematically from these samples confirm HLA typing and determine the TNC and CD34+ cell viability. FACT-NETCORD accreditation (sixth edition, September 2015) incorporated specifications for the viabilities obtained on the AS without precision on control quality technique to be used (470% for CD34+ cells and 440% for TNC).
Few studies have assessed the representativeness of quality controls performed on AS vs bags. [3] [4] [5] [6] [7] [8] [9] In these studies, the TNC/ CD45+/mononuclear cells viability obtained on the AS was very heterogeneous (39-91%). Two articles reported AS viability values for CD34+ cells, 74 ± 16 and 96.6 ± 4.6%. 6, 7 The results obtained are discordant according to centers, probably due to heterogeneity of the freezing methods, thawing methods and quality control as demonstrated by comparison between 7-AAD and trypan blue. 3, 6 The result difference between ASs and bags can be explained by the freezing process, which cannot be similar since these two compartments do not have the same geometry and volume. This element leads us to question the actual relevance of the ASs on the UCB bag contents. Results obtained from the grafted, quality control program or canceled UCB indicate that the cell viabilities obtained from distal and proximal AS are not representative of those obtained on the bag. Moreover, cancellations represented 7% of UCB recruitments from our CBB. This rate demonstrates that a significant transplant number is impacted, whereas it should be noted that the viabilities we obtained for the cells present in the bag were compliant with our specifications. To conclude, the viabilities obtained on the ASs in our study are not predictive of the bag HSC quality. The decision not to recruit a UCB unit on this criterion may represent a loss of opportunity for patients. We suggest giving importance to the pre-freezing data whose value in predicting post-thaw results has been demonstrated by both Kudo et al. 5 and Solves et al. 8 It will also be necessary to ensure that the CBB are certified by the governmental authorities of the country or by JACIE and/or FACT-NETCORD accreditation, which will ensure the processing and storage of the UCB units. 
